| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
SVP, General Counsel | General Counsel
1 company
Douglas Earl Martin is a SVP, General Counsel at Allogene Therapeutics, Inc.. Recent SEC Form 4 filings include 0 buys and 1 sell.
Estimated insider holdings value: $1.2M based on current market prices.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 3, 2025 | ALLO Allogene Therapeutics, Inc. | SVP, General Counsel | Sell | 6,404 | $1.71 | $10,950.84 | -1.1% | -3.0% | +4.2% |